Sources of variability in echocardiographic measurements

Felner, Joel M.; Blumenstein, Brent A.; Schlant, Robert C.; Carter, Anthony D.; Alimurung, Benjamin N.; Johnson, Melvin J.; Sherman, Stanley W; Klicpera, M; Kutner, Michael; Drucker, Louise W.

doi:10.1016/0002-9149(80)90168-x

Cited by 60 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The echocardiography was supervised by two examiners each having more than 5 years' experience and measurements were made according to the method of Felner et al (1980). In the presence of enlarged cardiac size or dyskinesis, calculations of the cardiac volume based on M-mode echocardiography are unreliable (Popp et al, 1973;Teicholz et al, 1976).…”

Section: Measurementsmentioning

confidence: 99%

The cardiovascular effects of xamoterol, a beta 1‐adrenoceptor partial agonist, in healthy volunteers at rest.

Hashimoto¹,

Shiina²,

Toyo’oka³

et al. 1986

Brit J Clinical Pharma

View full text Add to dashboard Cite

School, Minamikawachi-machi, Tochigi Prefecture, Japan 1 The cardiovascular effects of three single intravenous doses of a Pl-adrenoceptor partial agonist, xamoterol (0.025, 0.05 and 0.1 mg kg-') and placebo were studied in six healthy volunteers at rest using a single-blind design. 2 In addition to heart rate and blood pressure measurements, cardiac contractility was measured by means of M-mode echocardiography and systolic time intervals. Ambulatory 24 h Holter-monitoring of the electrocardiogram was performed. Plasma concentrations of xamoterol were measured. 3 Compared to baseline, xamoterol (0.025 mg kg-) increased heart rate (61 + 3-68 ± 3 beats min-1, means and SEM) and systolic blood pressure (119 ± 3-138 + 5 mm Hg) but decreased pre-ejection period (100 + 4-76 + 5 msec). Stroke volume (88 ± 6-104 + 10 ml), cardiac output (4.8 ± 0.4-6.6 ± 0.6 1 min-'), velocity of circumferential fibre shortening (1.15 ± 0.06-1.50 ± 0.06 circ s-1) were increased by xamoterol. No significant changes were produced by placebo. 4 No dose-dependent effects were seen and maximum effects were produced by 0.025 mg kg-' xamoterol. Significant effects were observed for 2 h. The areas under the plasma concentration curves (AUCO.12) showed a linear dose response.

show abstract

Section: Measurementsmentioning

confidence: 99%

The cardiovascular effects of xamoterol, a beta 1‐adrenoceptor partial agonist, in healthy volunteers at rest.

Hashimoto¹,

Shiina²,

Toyo’oka³

et al. 1986

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…interobserver variability, echocardiographic reproducibility Earlier studies in echocardiographic measurement variability have shown varying results (Felner et al, 1980; Ladipo et al, Vignola et al, 1977).…”

mentioning

confidence: 99%

Evidence of no interobserver variability in m‐mode echocardiography

Leonardis

Cinelli

1986

Clinical Cardiology

View full text Add to dashboard Cite

Summary: Left ventricular internal dimensions, septal and posterior wall thickness, aortic root diameter, and left atrial dimensions, were independently measured by two experienced interpreters on 50 consecutive routinely performed M-mode echocardiograms. The purpose of this work was to evaluate the reproducibility of these measurements and to assess if a different "diagnostic effect" could be provided by the two readers. The extent of interobserver variability was calculated and expressed as a percent of the mean. No significant interobserver variability was found for all the measured echocardiographic parameters and the two interpreters gave rise to the same "diagnostic effects." Therefore, the authors suggest following well stated guidelines to provide uniformity in the process of determining the boundaries of the structures to be measured and adjusting the actual measurements by multiplying by a conversion factor (representing the ratio between the number of 1 cm markers and the distance in centimeters between the first and the last marker), as opposed to interpolating between the marks on the recording paper.

show abstract

“…21 Experimental factors have been evaluated in interpretation and in testing protocol (subject gender, day and time done, subject position) that might be involved in the variability of echocardiographic measurements. 22 Using a variance component model, the relative contribution of various factors to the total variability in measurement was demonstrated. As expected, the subject variance was a major component in all measurements.…”

Section: Resultsmentioning

confidence: 99%